Veradermics is a late clinical-stage aesthetics and dermatology-focused biopharmaceutical company developing first-in-class treatments for common dermatologic conditions. The company's lead candidate, VDPHL01, is a non-hormonal oral therapeutic that is currently being evaluated for the treatment of AGA/PHL in both men and women. Additional pipeline programs address common dermatologic conditions including common warts and molluscum contagiosum.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/18/24 | $75,000,000 | Series B |
Connecticut Innovations JW Childs Associates Longitude Capital Osage University Partners PhiFund Surveyor Capital Suvretta Capital Management  Vlad Coric | undisclosed |
